Skip to main content
. 2018 May 15;9(37):24731–24736. doi: 10.18632/oncotarget.25340

Figure 1. Cirmtuzumab inhibits Wnt5a-Induced Rac1 activation in ibrutinib-treated MCL cells.

Figure 1

(A) DMFI of ROR1 in MCL vs CLL (n = 8). The P value was determined by Student’s t test; ns = not significant. (B) Plasma Wnt5a in patients with MCL versus age-matched control subjects (n = 4 per group; P < 0.05, Student’s t test). (C) Activated Rac1 was measured in MCL cells, which were treated with or without Wnt5a (200 ng/ml), with or without ibrutinib (0.5 µM), or with or without cirmtuzumab (10 μg/ml), as indicated above each lane of the immunoblot. The numbers below each lane are the ratios of band integrated optical density (IOD) of activated versus total Rac1 normalized to untreated samples (defined as the “IOD of Rac1”). (D) Depicts the mean IOD of Rac1, as defined in 1C, in Wnt5a-stimulated MCL cells treated with or without cirmtuzumab and/or ibrutinib observed in three independent experiments (± SEM). ****P < 0.0001, as calculated using one-way ANOVA with Tukey’s multiple comparisons test.